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IMPORTANCE Therapeutic options for severe emphysema are limited. Lung volume reduction
using nitinol coils is a bronchoscopic intervention inducing regional parenchymal volume
reduction and restoring lung recoil.
OBJECTIVE To evaluate the efficacy, safety, cost, and cost-effectiveness of nitinol coils in
treatment of severe emphysema.
DESIGN, SETTING, ANDPARTICIPANTS Multicenter 1:1 randomized superiority trial comparing
coilswithusual care at 10university hospitals in France. Enrollmentof patientswith emphysema
occurred fromMarch toOctober 2013,with 12-month follow-up (last follow-up,December 2014).
INTERVENTIONS Patients randomized to usual care (n = 50) received rehabilitation and
bronchodilators with or without inhaled corticosteroids and oxygen; those randomized to
bilateral coil treatment (n = 50) received usual care plus additional therapy in which
approximately 10 coils per lobe were placed in 2 bilateral lobes in 2 procedures.
MAIN OUTCOMES ANDMEASURES The primary outcomewas improvement of at least 54m in
the 6-minute walk test at 6months (1-sided hypothesis test). Secondary outcomes included
changes at 6 and 12months in the 6-minute walk test, lung function, quality of life as
assessed by St George’s Respiratory Questionnaire (range, 0-100; 0 being the best and 100
being the worst quality of life; minimal clinically important difference,4), morbidity,
mortality, total cost, and cost-effectiveness.
RESULTS Among 100 patients, 71 men and 29women (mean age, 62 years) were included. At
6months, improvement of at least 54mwas observed in 18 patients (36%) in the coil group
and 9 patients (18%) in the usual care group, for a between-group difference of 18% (1-sided
95% CI, 4% to; P = .03). Mean between-group differences at 6 and 12months in the coil
and usual care groups were +0.09 L (95% CI, 0.05 L to) (P = .001) and +0.08 L (95% CI,
0.03 L to) (P = .002) for forced expiratory volume in the first second, +21 m (95% CI,
−4m to) (P = .06) and +21 m (95% CI, −5 m to) (P = .12) for 6-minute walk distance, and
−13.4 points (95% CI, −8 points to) and −10.6 points (95% CI, −5.8 points to) for
St George’s Respiratory Questionnaire (1-sided P < .001 for both). Within 12 months, 4 deaths
occurred in the coil group and 3 in the usual care group. Themean total 1-year per-patient
cost difference between groups was $47 908 (95% CI, $47 879-$48073) (P < .001); the
incremental cost-effectiveness ratio was $782 598 per additional quality-adjusted life-year.
CONCLUSIONS AND RELEVANCE In this preliminary study of patients with severe emphysema
followed up for 6months, bronchoscopic treatment with nitinol coils compared with usual
care resulted in improved exercise capacity with high short-term costs. Further investigation
is needed to assess durability of benefit and long-term cost implications.
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Emphysema,akeycomponentofchronicobstructivepul-monary disease, is characterized by lung tissue inelas-ticity, air trapping, and hyperinflation, causing dys-
pnea, exercise limitation, and impaired quality of life.
Management of severe emphysema represents a challenge be-
causeof limitedefficacyofcurrentlyavailable treatments.Lung
volume reduction surgery
demonstrated improved
overall survival and better
clinicalandfunctionalout-
comes, particularly in pa-
tients with upper lobe–
predominant emphysema
and low exercise capacity.1,2 However, lung volume reduction
surgery is associated with significant morbidity andmortality.
A number of minimally invasive interventional strategies, in-
cluding endobronchial valves,3,4 airway bypass,5 biological
sealants,6 thermalvaporablation,7 andendobronchial coils,8-14
havebeenevaluated.Endobronchialvalvesshowedclinicallysig-
nificant improvements in selected patients with upper lobe–
predominant emphysema4 andwith intact fissures.3,4
Shape-memorynitinol coils arenonblockingdevicesbron-
choscopically delivered into subsegmental airways to induce
regional parenchymal volume reduction, enhance lung re-
coil, and reestablish small airway tethering.Todate, coils have
been investigated in 5nonrandomized studies8-11,13 and 1 ran-
domized, controlled 90-day crossover study.12,14 These stud-
ies reported that coil treatmentprovided improvement inqual-
ity of life, exercise capacity, and lung function.
Highcostsareassociatedwith lungvolumereductionstrat-
egies for severe emphysema.2,15 Acceptance of new therapies
should consider evidence of cost-effectiveness. Because the
health economic evidence base for bronchoscopic interven-
tional strategies is minimal,15 the current study design in-
cluded a cost-effectiveness analysis.
TheREVOLENStrial (RéductionVolumiqueEndobronchique
par Spirales)was designed to evaluate the efficacy, safety, cost,
and cost-effectiveness of coil treatment in severe emphysema.
Methods
Study Oversight
Ten sites throughout France participated in the study. This
studywasapprovedby theEthicsCommitteeofDijonEst I and
by the French Agency for Medicines and Health Products. A
website was accessible to participants and referring physi-
cians (http://www.euroemphysema.com). Enrollment of par-
ticipants started in March 2013 and was completed in Octo-
ber 2013. The last follow-up visit was in December 2014. An
independent data and safety monitoring board monitored
eventsandreviewedefficacyresults.Thetrialprotocolhasbeen
previouslypublished16and isavailable inSupplement 1.Allpar-
ticipants provided written informed consent.
Patient Population and Randomization
Eligible patients were randomized in a 1:1 fashion to receive
usual careor coilsusingacentralizedcomputer-generated ran-
domization system with fixed blocks of 4. The main inclu-
sion criteria were bilateral emphysema, postbronchodilator
forcedexpiratoryvolume in the first second (FEV1) of less than
50%predicted, residualvolume (RV)ofgreater than220%pre-
dicted, and formal pulmonary rehabilitation within the pre-
vious 12 months (eBox in Supplement 2).
Emphysema was quantified in each lobe using the Na-
tional EmphysemaTreatmentTrial visual assessment score.17
Themost severely affected lobe of each lungwas targeted for
coil treatment and the upper lobe was chosen when ipsilat-
eral scores were the same. Scoring and targeting were deter-
mined by each site. No computed tomography densitometry
analysis was used in this study.
Usual Care Group
Patients were treated at the discretion of the patient’s physi-
cian in compliance with international guidelines; ie, they re-
ceived prerandomization rehabilitation, inhaled bronchodi-
lators, and influenza and pneumococcal vaccination, with or
without inhaled corticosteroids and with or without oxygen,
according to the degree of severity and exacerbation rate.
Intervention Coil Group
Patients in the coil group received the same treatment as the
usual caregroupandalso receivedcoil treatmentwithin 15days
after randomization. The contralateral treatment was com-
pleted 1 to 3 months after the first. All coil insertion proce-
dureswere conductedunder general anesthesia using fluoros-
copytoguideplacement(eFigures1and2inSupplement2).Two
sizes of coil (100mmand 125mm; PneumRx/BTG)were avail-
able. Approximately 10 coils per targeted lobe were delivered.
Thecoil group receivedamoxicillin/clavulanic acid, 2g (or clin-
damycin,600mg,andgentamycin,5mg/kg, ifallergic toamoxi-
cillin), immediatelybeforetheprocedure.Chestradiographywas
performed within 2 hours of and at 24 hours after the proce-
dure (eFigure 3 in Supplement 2). In the absence of significant
complications,patientsweredischargedat thediscretionof the
attending physician.
Follow-up
Allpatientswereassessedatbaselineandat1,3,6,and12months
after baseline. All patients underwent medical examination,
6-minutewalktestonroomair,chestx-ray,andpulmonaryfunc-
tion tests according to international guidelines.18 Patients com-
pleted dyspnea questionnaires using themodifiedMedical Re-
search Council dyspnea scale and the BaselineDyspnea Index/
Transition Dyspnea Index. The modified Medical Research
Councildyspneascalegrades5different levelsofdyspneabased
onthecircumstancesinwhichitarises:grade0,“Ionlygetbreath-
lesswithstrenuousexercise”;grade1,“Igetshortofbreathwhen
hurryingonlevelgroundorwalkingupaslighthill”;grade2,“On
levelground, Iwalkslower thanpeopleof thesameagebecause
ofbreathlessness,or Ihavetostopforbreathwhenwalkingatmy
ownpace on the level”; grade 3, “I stop for breath afterwalking
about 100 yards or after a fewminutes on level ground”; grade
4,“Iamtoobreathlessto leavethehouseorIambreathlesswhen
dressing.” Quality of lifewas assessed using the St George’s Re-
spiratoryQuestionnaire,rangingfrom0to100withhigherscores
FEV1 forced expiratory volume in the
first second
FVC forced vital capacity
QALY quality-adjusted life-year
RV residual volume
TLC total lung capacity
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indicatingworsequalityof life(0beingthebestand100beingthe
worstqualityof life,and−4pointsconsideredaminimalclinically
importantdifference), andtheEuroQol5DimensionsQuestion-
naireprovidedautilityvalueonascale rangingfrom0(death) to
1 (fullhealth).Allpatientshadathoraciccomputedtomography
scanatbaselineandthecoilgroupalsohadoneat6months.Medi-
cations and oxygen usewere recorded at each visit. Patients in
both groups continued their regular treatment.
Study End Points
Theprimary outcomewas improvement of at least 54m in the
6-minutewalktestat6months.Thecutoff todefinearesponder
wasbasedondata fromRedelmeieret al19 showing that thedis-
tances needed to differ by 54m for the average patient to stop
ratingthemselvesas“aboutthesame”andstartratingthemselves
aseither“a littlebitbetter”or“a littlebitworse.”Secondaryend
points were changes at 6 and 12 months from baseline in the
6-minutewalkdistance,pulmonaryfunctiontests (FEV1, forced
vital capacity [FVC],RV, total lungcapacity [TLC], andRV/TLC),
dyspnea(modifiedMedicalResearchCouncildyspneascaleand
BaselineDyspnea Index/TransitionDyspnea Index), andqual-
ityof life (StGeorge’sRespiratoryQuestionnaire andEuroQol 5
Dimensions Questionnaire) in each group.
The safety outcomes included all nonserious and serious
adverse events. In the coil group, serious adverse eventswere
stratified by occurrence within 30 days vs after 30 days to 12
months. A composite score included any of the following se-
rious adverse events occurring within 24 hours after treat-
ment: death, pneumothorax requiring chest tube placement
formore than7daysor surgical treatment, hemoptysis greater
than 150mL, and invasive ventilation formore than24hours.
A second composite score also included the following serious
adverse events occurring within 12 months in both groups:
death, hemoptysis greater than 150 mL, pneumonia requir-
inghospitalization, pneumothorax requiring chest tubeplace-
ment formore than7daysor surgical treatment, invasiveven-
tilation for more than 24 hours, and lung transplantation.
Economic Evaluation
Theprospectiveeconomicevaluationwasconcurrentwith the
randomized trial, inaccordancewith theCHEERSstatement.20
The prospective analysis was conducted from the health care
perspective to determine the cost per quality-adjusted life-
year (QALY) gained with coils compared with usual care over
a 1-year period. Bothhospital andnonhospital resourceswere
considered. Procedure costs for coil treatmentwere obtained
withabottom-upmicrocostingapproach that identifiedall rel-
evant cost componentsof theprocedureandvaluedeachcom-
ponent for all individual patients using duration of the proce-
dure, staff, medical devices, and type of operating room as
variables. Unit costs are presented in eTable 1 in Supplement
2. All costs are in 2014US dollars (US $1 = €0.754 in 2014) and
are not discounted because of the short time horizon.
Healthoutcomesarevalued inQALYs.Health-relatedqual-
ity of life was assessed using the EuroQol 5 Dimensions self-
administeredquestionnaires at baseline, 6months, and 1 year.
TheutilityvaluesarebasedonFrenchtariffs for thecorrespond-
ing EuroQol 5Dimensions scores. Utility curveswere obtained
for each group by plotting average utility values at baseline, 6
months,and1year.ThedifferenceinQALYswasestimatedasthe
difference intheareabetweentheutilitycurvesfor the2groups.
Acost-effectivenessanalysiswasconducted toestimate in-
cremental costsper incrementalQALY. Incremental costswere
taken as the difference in per-patient costs between groups.
Baseline characteristics, QALYs, and costs are described
using counts (and proportions), means (with standard devia-
tions or 95% confidence intervals), or medians (with inter-
quartile ranges). Differences in costs and QALYs were tested
using standard parametric or nonparametric tests (t test or
Mann-Whitney test) as appropriateandaredescribedasmeans
(with 95% confidence intervals). The incremental cost differ-
ence and generated 95% confidence intervals were calcu-
lated using nonparametric bootstrapping with 1000 replica-
tions. An acceptability curve was generated based on the
bootstrap results. Statistical significance fordifferencesamong
a priori comparisons was set at P = .05 (2-sided).
Statistical Analyses
The statistical power todemonstrate a superior success rate (1-
sidedhypothesis test) in theprimaryendpoint for thecoilgroup
vs the usual care group was anticipated to be 90% with a sig-
nificanceof α = .05 at a total sample sizeof 100patients, based
on the hypothesis of a 37% end-point achievement in the coil
group and5% in theusual care group andwith 30%ofpatients
unable to perform the 6-minute walk test or lost to follow-up
at 6 months. The hypothesis of a 37% primary end-point
achievement in the coil group was based on data provided by
PneumRx in 2012. One-sided statistical tests were considered
appropriate inviewof the favorable results ofprevious smaller
studies9-14,21 and confirmed by a recent meta-analysis.22 The
sample sizewas calculatedusingNquery software, version 7.0
(Statistical Solutions Ltd).
Variables are presentedusingmeanswith standarddevia-
tions or raw numbers and percentages. Differences at base-
line between groupswere analyzed using the χ2 test, t test, or
Fisher exact test.
For theprimaryendpoint, intention-to-treatanalyseswere
conductedusingamultiple imputationmethodformissingdata
usingSASproceduresPROCMIandPROCMIANALYSE(SASver-
sion 9.3, SAS Institute Inc). A logit model was used to impute
theoutcomeforparticipantswhodidnotperformthe6-minute
walk test at 6 months, based on the parameters of FEV1, FVC,
RV, St George’s Respiratory Questionnaire total score, modi-
fiedMedicalResearchCouncildyspneascale, andBaselineDys-
pnea Index/Transition Dyspnea Index. Ten imputations were
performed.Bivariable logisticmodelswere then fittedwith the
imputed values using treatment group as the predictor vari-
able. An additional maximum bias analysis considering pa-
tients who did not perform the 6-minute walk test to be non-
responders for the primary end point was also conducted.
The secondary end points for efficacy (1-sided test) and
safety (2-sided test) outcomeswere analyzed using the χ2 test,
t test,orFisherexacttest,orWilcoxontestwhenapplicable,with
no data imputation. For quantitative end points, mean differ-
ences and 1-sided 95% confidence intervals were reported. All
end points were assessed by intention-to-treat analysis.
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An independent data monitoring team ensured 100%
source verification of the data. Statistical analyses were per-
formed according to a prespecified statistical analysis plan
(available in Supplement 3).No intermediary statistical analy-
ses were conducted. A 1-sided P < .05 was considered statis-
tically significant for the efficacy analysis. No adjustment of
significance levelwasused for thesecondaryendpoints,which
were then exploratory. A 2-sided P < .05 was considered sta-
tistically significant for baseline between-group compari-
sons and for safety analyses. SAS software, version 9.3 (SAS
Institute Inc) was used for statistical analysis.
Results
Patients and Procedures
Of 116 patients who consented, 100 patients were random-
ized to the coil (n = 50) or usual care (n = 50) groups (Figure).
Baseline characteristics are shown in Table 1. Among the 50
patients randomized to the coil group, 47patients receivedbi-
lateral and 3 received unilateral coil treatment (Figure), for a
total of 97 procedures (eTable 3 in Supplement 2). A mean of
9.8 (SD, 1.3) coils per procedure were placed. The mean pro-
cedure time was 54 (SD, 17) minutes.
Primary End Point
Six-minutewalktestresultswereavailablefor44patients ineach
group at 6months. Sixteen patients in the coil group and 8 pa-
tients in theusual caregroupachieveda6-minutewalk test im-
provement of at least 54m at 6months. Usingmultiple impu-
tation formissing data, 18 patients (36%) in the coil group and
9patients(18%)intheusualcaregroupachieveda6-minutewalk
test improvement of at least 54mat 6months (P = .03), with a
meanbetween-groupdifferenceof18%(95%CI,4%to) (Table2
andeFigure4inSupplement2). Inamaximumbiasanalysiscon-
sideringpatientswhodidnotperformthe6-minutewalk test to
benonresponders for theprimaryendpoint, thePvaluewas .03.
The primary end pointwas therefore achieved.
Secondary Efficacy End Points
The secondary efficacy end points at 6 and 12 months are
shown in Table 2. At 6 months, improvements from baseline
were significant in thecoil groupcomparedwith theusual care
group in the 6-minute walk test (when analyzed as percent
changebutnotwhenanalyzedbydistancewalked),FEV1,FVC,
RV,RV/TLC,modifiedMedicalResearchCouncildyspneascale,
Transition Dyspnea Index, and St George’s Respiratory Ques-
tionnaire (allP < .05).At 12months, improvements frombase-
linewere significant in the coil groupcomparedwith theusual
care group for FEV1, FVC, RV, RV/TLC, modified Medical Re-
search Council dyspnea scale, and St George’s Respiratory
Questionnaire (all P < .05) but not for the 6-minutewalk test.
Quantitatively, themeanbetween-groupdifferences for the
secondary end points in the coil and usual care groups were
at6and12months, respectively, 11%(95%CI,6%to;P = .001)
and 11% (95% CI, 5.2% to ; P = .002) for FEV1, −7% (95% CI,
Figure. Flow of Participants in the REVOLENS Study
116 Patients consented to study screening
16 Excluded
9 Lung carcinoma or pulmonary nodule on
thoracic CT scan requiring follow-up CT scan
1 Systolic pulmonary artery pressure >50 mm Hg
1 Residual volume <220%
1 FEV1 >50%, residual volume <220%, and pulmonary
nodule on thoracic CT scan requiring follow-up CT scan
1 Nonbilateral emphysema
1 Contraindication to general anesthesia
1 Eligible but study closed at the time of randomization
1 Extrapulmonary disease compromising survival
or evaluation
100 Randomized
50 Randomized to receive coil 
treatment
47 Received bilateral coil
treatment
3 Received unilateral coil
treatment a
47 Followed up at 6 mo
3 Died prior to 6-mo follow-up
50 Included in primary analysis
44 Followed up at 12 mo
1 Died prior to 12-mo follow-up
2 Not available for follow-up b
50 Randomized to receive
usual care
50 Received usual care as
randomized
49 Followed up at 6 mo
1 Died prior to 6-mo follow-up
50 Included in primary analysis
47 Followed up at 12 mo
2 Died prior to 12-mo follow-up
CT indicates computed tomography;
FEV1, forced expiratory volume in the
first second.
a The reasons for not performing
bilateral treatment were death
before second treatment (n = 1),
anaphylactic shock at induction of
anesthesia for the second coil
treatment (n = 1) (further analyses
demonstrated allergy to penicillin),
and pneumonia after the first coil
treatment leading to unwillingness
of the patient to undergo a second
coil treatment (n = 1).
b These 2 patients were alive at 12
months but did not attend the
planned visit at 12 months.
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−2% to −; P = .009) and −7% (95%CI, −2.6% to −; P = .003)
for RV, 8% (95% CI, −2.7% to ; P = .048) and 7.1% (95% CI,
−2.2% to ; P = .09) for the 6-minute walk test, −13.4 points
(95% CI, −8 points to −; P < .001) and −10.6 points (95% CI,
−5.8 points to −; P < .001) for quality of life assessed by the
St George’s Respiratory Questionnaire, −0.45 units (95% CI,
−0.17 units to −; P = .01) and −0.4 units (95%CI, −0.05 units
to −; P = .02) for dyspnea assessed by themodified Medical
Research Council scale, and 1.6 points (95% CI, 0.54 points
to; P = .04) and 1.1 points (95%CI, −0.5 points to ; P = .08)
for the Transition Dyspnea Index.
A post hoc analysis did not find any difference regarding
efficacy between homogeneous and heterogeneous emphy-
sema (eTable 2 in Supplement 2).
Safety Outcomes
Serious adverse events are presented in Table 3 and nonseri-
ous adverse events are presented in eTable 4 in Supplement 2.
Pneumonia was themost frequent serious adverse events, in-
cluding11events in9patients(18%)inthecoilgroupand2events
in 2 patients (4%) in the usual care group within 1 year, with a
difference between groups of 14% (95% CI, 2%-26%; P = .03).
Overall, at least 1 serious adverse event occurred within 1 year
in 26 patients (52%) in the coil group and in 19 patients (38%)
in theusual caregroup,withabetween-groupdifferenceof 14%
(95%CI, −5% to 33%; P = .16). The serious adverse event com-
posite scorewithin 12months included 17 events in 14patients
(28%) in the coil group and 8 events in 6 patients (12%) in the
usual care group, with a difference between groups of 16%
Table 1. Baseline Participant Characteristicsa
Characteristics
Coil Treatment
(n = 50)
Usual Care
(n = 50)
Age, y 62.1 (8.3) 61.9 (7.3)
Men, No. (%) 39 (78) 32 (64)
Pack-years smoked 44 (19) 46 (21)
Body mass indexb 22.5 (4.1) 23 (4.3)
6-Minute walk test distance, m 300 (112)c 326 (121)
Modified Medical Research Council
dyspnea scale score, No. (%)d
1 0 1 (2)e
2 11 (22) 13 (26)
3 28 (56) 25 (50)
4 11 (22) 11 (22)
Baseline Dyspnea Index scoref 4.4 (2.1) 4.1 (1.9)
FEV1, % predicted 25.7 (7.5) 27.4 (6.2)
FEV1, L 0.75 (0.25) 0.77 (0.22)
FVC, % predicted 67.4 (16.5) 72 (20.1)
FVC, L 2.45 (0.61) 2.53 (0.82)
FEV1/FVC ratio 0.31 (0.09) 0.32 (0.08)
RV, % predicted 271.2 (38.1) 269.3 (44.3)
RV, L 6.2 (0.86) 6 (1.18)
TLC, % predicted 141.7 (16.6) 143.6 (18)
TLC, L 8.85 (1.03) 8.66 (1.35)
RV/TLC ratio 0.70 (0.06) 0.69 (0.07)
St George’s Respiratory Questionnaire scoreg
Impact 49.4 (17.2) 44.9 (16.7)
Activity 81.8 (11.5) 78.5 (13.7)
Symptoms 58.2 (17.1) 56.2 (19.8)
Total 60.8 (12.8) 57.1 (14.1)
Emphysema scoreh
Right upper lobe 2.9 (0.7) 3.2 (0.8)
Middle lobe 2.1 (1) 2.3 (0.8)
Right lower lobe 2.2 (0.9) 2.2 (0.8)
Left upper lobe 2.9 (0.8) 3 (0.7)
Left lower lobe 2.3 (0.9) 2.2 (1)
Heterogeneous, No. (%)i 17 (34) 16 (32)
Treatments, No. (%)
Oxygen therapy 32 (64) 29 (58)
Long-action β-agonists 49 (98) 48 (96)
Long-acting muscarinic antagonists 45 (90) 42 (84)
Inhaled corticosteroids 46 (92) 43 (86)
Abbreviations: FEV1, forced
expiratory volume in the first second;
FVC, forced vital capacity;
RV, residual volume; TLC, total
lung capacity.
a Values are shown as mean (SD)
unless otherwise indicated. There
were no between-group differences
in baseline characteristics
(2-sided test).
b Bodymass index was calculated as
weight in kilograms divided by
height in meters squared.
c The 6-minute walk test was
conducted with 1 patient receiving
oxygen in error, and the patient was
retained for further follow-up and
included in analyses.
d Themodified Medical Research
Council dyspnea scale grades 5
different levels of dyspnea based on
the circumstances in which it arises.
SeeMethods section of text for
description.
e One patient with a modified Medical
Research Council dyspnea scale
score of 1 was included in error but
was included in the follow-up and
analyses.
f The Baseline Dyspnea Index uses 5
grades (0-4) for 3 categories,
functional impairment, magnitude
of task, andmagnitude of effort,
with a total score of 0 to 12. Higher
scores indicate less dyspnea.
g The St George’s Respiratory
Questionnaire (range, 0-100) has 3
component domains (impact,
activity, and symptoms) measuring
quality of life. Higher scores indicate
worse quality of life.
h A visual score from0 to 4 was
assigned to each lobe, based on the
extent of tissue destruction, where
0 = no emphysema, 1 = 1% to 25%
emphysematous, 2 = 26% to 50%,
3 = 51% to 75%, and 4 = >75%.
i Emphysemawas classified as
heterogeneous if there was a
difference of greater than 1 point
between ipsilateral lobes.
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Table 2. Primary and Secondary Intention-to-Treat Efficacy End Points
Outcomes
Coil Treatment
(n = 50)
Usual Care
(n = 50)
Difference
(1-Sided 95% CI) P Valuea
Primary End Point
6-Minute walk test, ≥54 m improvement,
No. (%)b
18 (36) 9 (18) 0.18 (0.04 to ) .03
Secondary End Points at 6 mo, Mean (95% CI)
6-Minute walk test improvement, m 18 (−6 to 43) −3 (−22 to 16) 21 (−4 to ) .06
% Change 9 (−1 to 20) 1 (−6 to 9) 8 (−2.7 to ) .048
Dyspnea
Modified Medical Research Council
dyspnea scale score
−0.5 (−0.8 to −0.2) −0.1 (−0.3 to 0.1) −0.45 (−0.17 to −) .01
Transition Dyspnea Index total scorec 0.8 (−0.3 to 2.0) −0.8 (−1.6 to 0) 1.6 (0.54 to ) .04
Pulmonary function
FEV1, L 0.06 (0.02 to 0.11) −0.03 (−0.05 to 0) 0.09 (0.05 to ) .001
% Change 9 (4 to 14) −3 (−6 to 1) 11 (6 to ) .001
FVC, L 0.26 (0.11 to 0.40) 0.05 (−0.12 to 0.22) 0.21 (0.03 to ) .03
% Change 15 (7 to 21) 5 (−2 to 12) 10 (1.5 to ) .01
RV, L −0.52 (−0.74 to −0.31) −0.15 (−0.41 to 0.11) −0.37 (−0.09 to −) .01
% Change −9 (−12 to −5) −2 (−6 to 2) −7 (−2 to −) .009
TLC, L −0.34 (−0.50 to −0.18) −0.14 (−0.35 to 0.06) −0.20 (0.03 to −) .09
% Change −4 (−6 to −2) −2 (−4 to 1) −2.0 (0.3 to −) .10
RV/TLC ratio −0.04 (−0.05 to −0.02) −0.01 (−0.03 to 0.01) −0.03 (−0.01 to −) .01
% Change −5 (−8 to −3) −1 (−4 to 2) −5.2 (−1.5 to −) .01
Quality of life
St George’s Respiratory Questionnaire score
Total −11.1 (−15.9 to −6.2) 2.3 (−1.3 to 5.9) −13.4 (−8 to −) <.001
Impact −12.5 (−18.1 to −6.8) 1.7 (−2.2 to 5.6) −14.0 (−9 to −) <.001
Activity −11.3 (−16.3 to −6.2) 0.7 (−2.7 to 4.1) −12.0 (−7 to −) <.001
Symptoms −4.7 (−11.5 to 2.1) 4.3 (−2.5 to 11.0) −9.0 (−1.1 to −) .04
Secondary End Points at 12 mo, Mean (95% CI)
6-Minute walk test improvement, m −2 (−29 to 25) −23 (−42 to −4) 21 (−5 to ) .12
% Change −0.05 (−10 to 10) −7.2 (−13 to −1) 7.1 (−2.2 to ) .09
Dyspnea
Modified Medical Research Council
dyspnea scale score
−0.5 (−0.8 to −0.1) −0.1 (−0.3 to −0.1) −0.4 (−0.05 to −) .02
Transition Dyspnea Index total scorec −0.2 (−1.9 to 1.4) −1.3 (−2.2 to −0.3) 1.1 (−0.5 to ) .08
Pulmonary function
FEV1, L 0.05 (0.01 to −0.10) −0.03 (−0.06 to 0.01) 0.08 (0.03 to ) .002
% Change 8 (3 to 13) −3 (−8 to 2) 11 (5.2 to ) .002
FVC, L 0.27 (0.12 to 0.43) 0 (−0.17 to 0.17) 0.27 (0.07 to ) .008
% Change 14 (7 to 21) 4 (−3 to 9) 10 (2.4 to ) .02
RV, L −0.47 (−0.67 to −0.26) −0.11 (−0.35 to 0.12) −0.36 (−0.10 to −) .004
% Change −9 (−12 to −5) −2 (−5 to 1) −7 (−2.6 to −) .003
TLC, L −0.29 (−0.49 to −0.09) −0.09 (−0.31 to 0.13) −0.20 (0.04 to −) .06
% Change −3 (−5 to −1) −1 (−3 to 1) −2 (0.3 to −) .06
RV/TLC ratio −0.03 (−0.05 to −0.02) 0 (−0.02 to 0.01) −0.03 (−0.01 to −) .007
% Change −5 (−7 to −2) 0 (−3 to 2) −5 (−1.6 to −) .008
Quality of life
St George’s Respiratory Questionnaire score
Total −9.1 (−14.1 to −4.2) 1.5 (−1.8 to 4.7) −10.6 (−5.8 to −) <.001
Impact −10.8 (−16.4 to −5.1) 1.8 (−2.5 to 6.0)) −12.6 (−6.8 to −) <.001
Activity −9.4 (−11.3 to −4.4) 2.8 (0.0 to 5.6) −12.2 (−7.5 to −) <.001
Symptoms −4.2 (−11.5 to 3.0) −3.9 (−8.7 to 0.9) −0.3 (6.7 to −) .45
Abbreviations: FEV1, forced expiratory volume in the first second; FVC, forced
vital capacity; RV, residual volume; TLC, total lung capacity.
a One-sided testing (χ2 or WilcoxonW tests).
bMultiple imputation for missing data.
c The Transition Dyspnea Index evaluates changes from the Baseline Dyspnea
Index. Higher scores indicate less dyspnea.
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(95%CI, 1%-31%;P = .046).Within12months,4deaths (8%)oc-
curredinthecoilgroupand3deaths(6%)intheusualcaregroup,
with a difference between groups of 2% (95% CI, −8% to 12%;
P = .99).Themost frequentnonseriousadverseeventwasmild
self-resolvinghemoptysis (< 5mL)within30daysafter thepro-
cedure (48%).
Health Economic Evaluation
Thehealth economic evaluationwas based ondata fromall 50
patients in each group. At 1 year, the mean cost difference per
patient was $47 908 (95% CI, $47 879-$48 073; P < .001)
(Table 4). The change inmeanQALYs at 1 year was 0.038 (95%
CI, 0.038-0.040) in the coil group vs −0.023 (95% CI, −0.025
to−0.023) intheusualcaregroup.ThemeandifferenceinQALYs
betweenthe2groupswas0.061 (95%CI,0.061-0.064;P = .02).
The 12-month incremental cost-effectiveness ratio was
$782 598 per QALY (95% CI, $663496-$1 327 212 per QALY).
The uncertainty associatedwith the cost-effectiveness of coil
treatment is shownas a scatter plot of themeancost andQALY
differences in eFigure 5Aand the acceptability curve is shown
in eFigure 5B in Supplement 2.
Discussion
To our knowledge, this is the first randomized multicenter
study assessing the 6-month efficacy, 1-year safety, and cost-
effectivenessofendobronchial coil treatment insevereemphy-
sema. Among patients followed up for 6 months, broncho-
scopic treatment with nitinol coils compared with usual care
resulted in improved exercise capacity with high short-term
costs. One of the main strength of this study is the complete-
ness of follow-up at both 6 and 12months. Coil treatment was
associatedwithasignificantdecrease in lunghyperinflationand
sustained improvement in quality of life. The magnitude of
changes in lung function and quality of life were very similar
Table 3. Serious Adverse Eventsa
Events
Coil Treatment (n = 50) Usual Care (n = 50)
Difference, %
(95% CI)b P Value
Patients,
No. (%)
No. of Events
Patients,
No. (%)
No. of Events
at 12 mo≤30 d >30 d to 12 mo
Chronic obstructive pulmonary disease
exacerbation
13 (26) 4 12 11 (22) 13 4 (−13 to 21) .64
Pneumothorax 3 (6) 3 1c 1 (2) 1 4 (−4 to 12) .62
Hemoptysis 1 (2) 1 0 0 0 2 (−2 to 6) .99
Thoracic pain 2 (4) 1 1 2 (4) 2 −2 (−9 to 5) .99
Pneumonia 9 (18) 5 6 2 (4) 2 14 (2 to 26) .03
Cardiovascular 1 (2) 1 0 3 (6) 3 −4 (−12 to 4) .62
Other 8 (16) 2 7 6 (12) 7 4 (−10 to 18) .56
Unknown 1 (2) 0 1 0 0 2 (−2 to 6) .99
Total 26 (52) 17 28 19 (38) 28 14 (−5 to 33) .16
Deaths 4 (8) 1d 3e 3 (6)f 3 2 (−8 to 12) .99
Composite score within 24 h
Death 0 0
Pneumothorax requiring chest tube
placement >7 d
1 (2) 1
Hemoptysis >150 mL 0 0
Invasive ventilation >24 h 0 0
Total 1 (2) 1
Composite score within 12 mo
Death 4 (8) 4 3 (6) 3 2 (−8 to 12) .99
Pneumothorax requiring chest tube
placement >7 d
1 (2) 1 0 0 2 (−2 to 6) .99
Hemoptysis >150 mL 0 0 0 0
Invasive ventilation >24 h 1 (2) 1 3 (6) 3 −4 (−12 to 4) .62
Pneumonia requiring hospitalization 9 (18) 11 2 (4) 2 14 (2 to 26) .03
Lung transplantation 0 0 0 0
Total 14 (28) 17 6 (12) 8 16 (1 to 31) .046
a Data are shown as No. of events and No. of patients with at least 1 serious
adverse event. Serious adverse events are stratified by occurrence within 30
days or between 30 days and 12months after treatment. Two-sided tests
were used for safety analyses.
bDifference between groups in the percentage of patients with events through
12months.
c Recurrence of pneumothorax after a first pneumothorax within 1 month after
procedure.
d The cause of death was peritonitis.
e The causes of death were chronic obstructive pulmonary disease
exacerbation, mesenteric ischemia, and unknown.
f The causes of death were chronic obstructive pulmonary disease exacerbation
in all 3 cases, associated with hepatitis in 1 case and associated with
mesenteric ischemia in 1 case.
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to results of uncontrolled studies assessing bilateral coil
treatment9-14 and to the resultsof a recentmeta-analysis.22The
changes in quality of life in our studywere higher thanusually
observed in endobronchial lung volume reduction clinical
trials.3,4Becauseourstudywasdesignedtomirror real-lifeclini-
cal decisionmaking, computed tomographyassessmentswere
conducted by each investigatorwithout central reading center
orproprietary softwareanalyses.Collateral ventilationwasnot
evaluated because fissure integrity did not influence response
to coil treatment.11 There was no difference in efficacy be-
tween heterogeneous and homogeneous emphysema, as pre-
viously shown.9,22 To evaluate coils as a therapeutic option
for patients typically excluded from lung volume reduction
trials, we did not exclude patients with 6-minute walk test
results of less than 140 m, diffusing capacity of the lungs for
carbon monoxide of less than 20% predicted, lower lobe–
predominantemphysema,homogeneousemphysema,hypox-
emia,hypercapnia, orα1-antitrypsindeficiencyorpatients tak-
ing anticoagulationdrugs (except for vitaminKantagonists) or
antiplateletdrugswithaspirinorclopidogrel.Ontheotherhand,
our inclusion criteria of an RV of greater than 220% predicted
wasmore restrictive than in previous coil treatment studies.22
Overall,ourpopulationwasauniqueseverelyhyperinflatedand
homogeneous emphysema population relative to other large
lung volume reduction trials.
Therewere several limitations to this study. First, thepre-
specified statistical analysis for efficacywas 1-tailed.Basedon
this method, the trial met its prespecified primary end point
for successat6months.However,additional largerstudieswith
longer follow-upusing 2-tailed statistical analyses areneeded
to draw a definitive conclusion regarding the long-term effi-
cacy of coil treatment. Second, this study was neither sham
controlled nor blinded, which needs to be considered for the
interpretation of the 6-minute walk test, which is effort de-
pendent. Third, the 6-minute walk test method was a single
test with no supplemental oxygen, and the cutoff to define a
responderwas 54m.19 The lack of practice of a second6-min-
ute walk test has been shown to increase the variance of this
measure.23 TheAmericanThoracic Society guidelines recom-
mend a standard oxygen titration protocol to determinewalk
Table 4. Resource Utilization and Costs by Randomization GroupOver a 12-Month Period
Resources
Coil Treatment
(n = 50)
Usual Care
(n = 50)
Difference
(95% CI) P Valuea
Total length of stay, mean (SD), d
First coil treatment 3.1 (1.6) NA
Second coil treatment 3.6 (2.5) NA
Patients with
≥1 rehospitalization,
No. (%)
15 (30)b 9 (18)b 6 .16
No. of rehospitalizations
per patient
Mean (SD) 0.5 (1) 0.2 (0.5) 0.3 (0.3 to 0.3) .21
Median (IQR) 0 (0-1) 0 (0-1)
Hospital costs, mean (SD), US $c
First coil treatment
Medical devices 20 214 (1943) NA
Staff 598 (158)
Operating room 560 (147)
Hospital stays 2882 (3084)
Median (IQR) 1399 (1399-3094)
Second coil treatment
Medical devices 18 395 (5061) NA
Staff 523 (191)
Operating room 492 (178)
Hospital stays 2883 (3053)
Median (IQR) 1399 (1399-3094)
Rehospitalization 1882 (4195) 910 (2675) 972 (952 to 1042) .14
Median (IQR) 0 (0-1170) 0 (0-0)
Consultation costs 1259 (1397) 1309 (1603) −50 (−69 to −32) .85
Median (IQR) 658 (403-1448) 601 (345-1561)
Transportation costs 351 (420) 160 (251) 191 (191 to 210) .01
Median (IQR) 211 (0-590) 0 (0-253)
Home oxygen costs 2947 (2553) 2706 (2564) 241 (212 to 275) .49
Monitoring tests 670 (95) 688 (48) −19 (−21 to −19) .29
Imaging 166 (27) 139 (9) 28 (28 to 28) <.001
Total 1-y costs 53 821 (10 475) 5912 (3529) 47 908 (47 879 to 48 073) <.001
Abbreviations: IQR, interquartile
range; NA, not applicable.
a P values were derived from 2-sided t
tests for equality of means.
b The total number of
rehospitalizations was 26 among 15
patients with a mean length of
hospital stay of 7.3 days (SD, 10.8
days) and amedian of 4 (IQR, 1-9) in
the coil group. The total number of
rehospitalizations was 11 among 9
patients with a mean length of
hospital stay of 3.5 days (SD, 3.8)
and amedian of 2 (IQR, 0-8) in the
usual care group (2-sided P = .17 for
the difference in length of stay
between the coil and usual care
groups).
c Costs are in 2014 US dollars; US
$1 = €0.754 in purchasing power
parity.
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oxygenprescription,whichwasused inother lungvolume re-
duction randomized trials.1-4The54-mcutoff is twice themost
recent minimal clinically important difference standards for
the 6-minute walk test, which are between 25m and 30m.24
Finally, a key factor influencing our 6-minute walk test out-
come may have been prebaseline pulmonary rehabilitation,
whichwasan inclusioncriterion inour study. Ina recentmeta-
analysis, themean change in the 6-minutewalk test result af-
ter rehabilitation inchronicobstructivepulmonarydiseasewas
estimated to be 43.9m.25 Our study showed a relativelymod-
estmagnitude of change, with a between-group difference of
21m in the6-minutewalk test at both6 and 12months,which
was statistically significant at 6monthswhenanalyzedasper-
cent change but not when analyzed by change in distance
walked and not significant at 12 months (although our study
was not powered for a 12-month end point). Compared with
themeta-analysis oncoil treatments,22 our6-minutewalkdis-
tance changes from baseline were much lower at both 6 and
12months, whereas the changes in lung function and quality
of life were in the same range. Finally, the absence of system-
atic prespecified continuation of rehabilitation after random-
ization could be regarded as an issue for the assessment of the
long-term benefits of the intervention.
Whenthebetween-groupdifferences in thesecondaryend
points were compared with validated minimal clinically im-
portant differences in chronic obstructive pulmonary dis-
ease, the improvement in quality of life assessed by the
StGeorge’sRespiratoryQuestionnairewas largelyhigher than
4 points26 at both 6 and 12 months (means, −13.4 and −10.6
points, respectively) and the improvement in dyspnea as-
sessedbytheTransitionDyspnea Indexwashigher than1unit27
at both 6 and 12 months (means, 1.6 and 1.1 units, respec-
tively). Themeanbetween-groupdifferences in changes inRV
at6and12monthswereboth7%androughly reachedthemini-
mal clinically important difference, which is a change be-
tween6.1%and8.6%.28ForFEV1, themeanbetween-groupdif-
ferenceswere0.09L at 6months and0.08L at 12months and
did not reach the minimal clinically important difference of
0.1 L.29
Themagnitudeand severity of serious andnonserious ad-
verse events in this study were consistent with previous coil
studies,22 similar to endobronchial valves,3,4 and far less than
for lung volume reduction surgery.1,2 The rate of pneumonia
was very similar to that recently reported in a meta-analysis
of 140patients treatedwith coils.22All cases of pneumonia re-
solvedwithmedical care. Themechanisms involved in pneu-
monia may result from local airway irritation, subsegmental
airway closure, tension-induced inflammation, or local ische-
mia rather than from an infectious mechanism. Additional
studies assessingpneumoniaor lungopacities associatedwith
coil treatment are needed to better understand the mecha-
nisms, risk factors, and short-term and long-term evolution.
Our study also demonstrated the feasibility of bilateral coil
treatment in this severely ill population; 94% of patients as-
signed to the coil group completed bilateral treatment.
The study design included a health economic analysis to
informhealth carepayers. The short durationof the follow-up
precluded any robust conclusion on the long-term efficiency
of the procedure because the procedure and device costs
should be allocated over the total duration of clinical benefit.
If we assumed that the QALYs gain could be maintained over
at least 3 years with identical follow-up costs in both groups,
the incremental cost-effectiveness ratio would decrease to
about $270 000 per QALY, close to the incremental cost-
effectiveness ratio reported for lungvolume reduction surgery
in theUnitedStates.30This cost-effectiveness ratioat 1yearand
modeled to 3 years would not be considered efficient enough
towarrant adopting the technology bymost countries. Imple-
mentationof this technique ina large-scale emphysemapopu-
lation is likely to require this additionaldatagiven thehighper-
patient cost in the short run and the uncertain effect on total
health care expenditures. Therefore, our study included both
a crossover and an extended (5-year) follow-up including a
health economic analysis of all treated patients.
Conclusions
In this preliminary study of patients with severe emphysema
followed up for 6 months, bronchoscopic treatment with ni-
tinol coils comparedwith usual care resulted in improved ex-
ercise capacitywith high short-term costs. Further investiga-
tion isneeded toassessdurabilityofbenefit and long-termcost
implications.
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